Incident cancer cases were invasive and consisted only of the first malignant neoplasm diagnosed during the follow-up period if multiple cancers had been diagnosed in the same participant. We defined cancers using the Surveillance Epidemiology and End Results site recode and the International Classification of Diseases for Oncology, Third Edition,16 code: head and neck (C000-C009, C019-C119, C129-C140, C142-C148, C300-C301, C310-C329, C339-C349, C381-C384, C388, C390, C398, and C399), esophageal (C150-C159), stomach (C160-C169), colorectal (C180-C189, C199, C209, and C260), liver (C220 and C221), pancreatic (C250-C259), lung (C340-C349), breast (C500-C509), ovarian (C569), endometrial (C540-C549 and C559), prostate (C619), bladder (C670-C679), kidney (C649 and C659), thyroid (C739), and brain (C710-C719) cancer. Non-Hodgkin lymphoma (NHL), leukemia, and myeloma were also defined by the Surveillance Epidemiology and End Results Program. Total cancer included those cancers listed above, skin cancer (excluding basal and squamous cell cancer), other miscellaneous cancers, and unspecified cancers. We also grouped cancers by anatomical area: head and neck, digestive system (C150-C189, C199, C209-C212, C218, C220-C221, C239-C260, C268-C269, C480-C482, and C488); respiratory system, excluding larynx (C300-C301, C310-C319, C339-C349, C381-C384, C388, C390, C398, and C399); reproductive system (men: C600-C609, C619-C639; women: C510-C519, C529-C549, C559, and C569-C589); urinary system (C649, C659, and C669-C689); brain and other nervous systems (C700-C729); endocrine system (C739-C759, and C379); and others.